OBJECTIVE: Clinical observations have suggested therapeutic effects for ω-3 fatty acids (O3FA) in Tourette's disorder (TD), but no randomized, controlled trials have been reported. In a placebo-controlled trial, we examined the efficacy of O3FA in children and adolescents with TD. METHODS:Thirty-three children and adolescents (ages 6-18) with TD were randomly assigned, double-blind, to O3FA or placebo for 20 weeks. O3FA consisted of combined eicosapentaenoic acid and docosahexaenoic acid. Placebo was olive oil. Groups were compared by using (1) intent-to-treat design, with the last-observation-carried-forward controlling for baseline measures and attention-deficit/hyperactivity disorder via (a) logistic regression, comparing percentage of responders on the primary Yale Global Tic Severity Scale (YGTSS)-Tic and secondary (YGTSS-Global and YGTSS-Impairment) outcome measures and (b) analysis of covariance; and (2) longitudinal mixed-effects models. RESULTS: At end point, subjects treated with O3FA did not have significantly higher response rates or lower mean scores on the YGTSS-Tic (53% vs 38%; 15.6 ± 1.6 vs 17.1 ± 1.6, P > .1). However, significantly more subjects on O3FA were considered responders on the YGTSS-Global measure (53% vs 31%, P = .05) and YGTSS-Impairment measure (59% vs 25%, P < .05), and mean YGTSS-Global scores were significantly lower in the O3FA-treated group than in the placebo group (31.7 ± 2.9 vs 40.9 ± 3.0, P = .04). Obsessive-compulsive, anxiety, and depressive symptoms were not significantly affected by O3FA. Longitudinal analysis did not yield group differences on any of the measures. CONCLUSIONS:O3FA did not reduce tic scores, but it may be beneficial in reduction of tic-related impairment for some children and adolescents with TD. Limitations include the small sample and the possible therapeutic effects of olive oil.
RCT Entities:
OBJECTIVE: Clinical observations have suggested therapeutic effects for ω-3 fatty acids (O3FA) in Tourette's disorder (TD), but no randomized, controlled trials have been reported. In a placebo-controlled trial, we examined the efficacy of O3FA in children and adolescents with TD. METHODS: Thirty-three children and adolescents (ages 6-18) with TD were randomly assigned, double-blind, to O3FA or placebo for 20 weeks. O3FA consisted of combined eicosapentaenoic acid and docosahexaenoic acid. Placebo was olive oil. Groups were compared by using (1) intent-to-treat design, with the last-observation-carried-forward controlling for baseline measures and attention-deficit/hyperactivity disorder via (a) logistic regression, comparing percentage of responders on the primary Yale Global Tic Severity Scale (YGTSS)-Tic and secondary (YGTSS-Global and YGTSS-Impairment) outcome measures and (b) analysis of covariance; and (2) longitudinal mixed-effects models. RESULTS: At end point, subjects treated with O3FA did not have significantly higher response rates or lower mean scores on the YGTSS-Tic (53% vs 38%; 15.6 ± 1.6 vs 17.1 ± 1.6, P > .1). However, significantly more subjects on O3FA were considered responders on the YGTSS-Global measure (53% vs 31%, P = .05) and YGTSS-Impairment measure (59% vs 25%, P < .05), and mean YGTSS-Global scores were significantly lower in the O3FA-treated group than in the placebo group (31.7 ± 2.9 vs 40.9 ± 3.0, P = .04). Obsessive-compulsive, anxiety, and depressive symptoms were not significantly affected by O3FA. Longitudinal analysis did not yield group differences on any of the measures. CONCLUSIONS:O3FA did not reduce tic scores, but it may be beneficial in reduction of tic-related impairment for some children and adolescents with TD. Limitations include the small sample and the possible therapeutic effects of olive oil.
Authors: L Scahill; P B Chappell; Y S Kim; R T Schultz; L Katsovich; E Shepherd; A F Arnsten; D J Cohen; J F Leckman Journal: Am J Psychiatry Date: 2001-07 Impact factor: 18.112
Authors: B J Coffey; J Biederman; D A Geller; T J Spencer; G S Kim; C A Bellordre; J A Frazier; K Cradock; M Magovcevic Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-05 Impact factor: 8.829
Authors: N Salem; T Moriguchi; R S Greiner; K McBride; A Ahmad; J N Catalan; B Slotnick Journal: J Mol Neurosci Date: 2001 Apr-Jun Impact factor: 3.444
Authors: T H Lee; R L Hoover; J D Williams; R I Sperling; J Ravalese; B W Spur; D R Robinson; E J Corey; R A Lewis; K F Austen Journal: N Engl J Med Date: 1985-05-09 Impact factor: 91.245
Authors: M A Riddle; E A Reeve; J A Yaryura-Tobias; H M Yang; J L Claghorn; G Gaffney; J H Greist; D Holland; B J McConville; T Pigott; J T Walkup Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-02 Impact factor: 8.829
Authors: Vilma Gabbay; Rachel D Freed; Carmen M Alonso; Stefanie Senger; Jill Stadterman; Beth A Davison; Rachel G Klein Journal: J Clin Psychiatry Date: 2018-06-26 Impact factor: 4.384
Authors: Tamara Pringsheim; Yolanda Holler-Managan; Michael S Okun; Joseph Jankovic; John Piacentini; Andrea E Cavanna; Davide Martino; Kirsten Müller-Vahl; Douglas W Woods; Michael Robinson; Elizabeth Jarvie; Veit Roessner; Maryam Oskoui Journal: Neurology Date: 2019-05-07 Impact factor: 9.910